8,9-去氢雌酮 | 474-87-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 8,9-去氢雌酮
• 中文别名: Δ-8,9-去羟基雌酮；3(2H)-呋喃酮,5-乙烯基二氢-2-亚丙基-,(2E,5R)-；Δ-8,9-脱氢雌酮
• 英文名称: 13β-methyl-3-hydroxygona-1,3,5(10),8-tetraen-17-one
• 英文别名: 8,9-Dehydroestrone；3-hydroxy-1,3,4(10),8,9-estratetraen-17-one；Δ^8,9-dehydroestrone；Δ8,9-dehydroestrone；8-dehydroestrone；3-hydroxyestra-1,3,5(10),8(9)-tetraen-17-one；(13S,14S)-3-hydroxy-13-methyl-7,11,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-17-one
• CAS: 474-87-3
• 化学式: C₁₈H₂₀O₂
• 分子量: 268.356
• InChiKey: OUGSRCWSHMWPQE-WMZOPIPTSA-N

物化性质

• 熔点：
  219-221°C
• 溶解度：
  乙醇（微溶）、甲醇（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  8,9-去氢雌酮 在 盐酸 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 3-hydroxy-estra-1,3,5(10),9(11)-tetraen-17-one
  参考文献：
  名称：

  975.完全合成的类固醇激素。第一部分。雌酮和相关的–strapolyenes

  摘要：

  DOI：

  10.1039/jr9630005072
• 作为产物：
  描述：

  6-羟基-1-四氢萘酮 在 咪唑 、 四丁基氟化铵 、 四氯化钛 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.25h， 生成 8,9-去氢雌酮
  参考文献：
  名称：

  Synthesis and Reactivity of the Catechol Metabolites from the Equine Estrogen, 8,9-Dehydroestrone

  摘要：

  The risk factors for women developing breast and endometrial cancers are all associated with a lifetime of estrogen exposure. Estrogen replacement therapy in particular has been correlated with an increased cancer risk. Previously, we showed that the equine estrogens equilin and equilenin, which are major components of the widely prescribed estrogen replacement formulation Premarin, are metabolized to highly cytotoxic quinoids which caused oxidative stress and alkylation of DNA in vitro [Bolton, J. L., Pisha, E., Zhang, F., and Qiu, S. Chem. Res. Toxicol. 1998, 11, 1113-1127]. In this study, we have synthesized 8,9-dehydroestrone (a third equine estrogen component of Premarin) and its potential catechol metabolites, 4-hydroxy-8,9-dehydroestrone and 2-hydroxy-8,9-dehydroestrone. Both 2-hydroxy-8,9-dehydroestrone and 4-hydroxy-8,9-dehydroestrone were oxidized by tyrosinase or rat liver microsomes to o-quinones which reacted with GSH to give one mono-GSH conjugate and two di-GSH conjugates. Like endogenous estrogens, 8,9-dehydroestrone was primarily converted by rat liver microsomes to the 2-hydroxylated rather than the 4-hydroxylated o-quinone GSH conjugates; the ratio of 2-hydroxy-8,9-dehydroestrone versus 4-hydroxy-8,9-dehydroestrone was 6:1. Also in contrast to experiments with equilin, 4-hydroxyequilenin was not observed in microsomal incubations with 8,9-dehydroestrone or its catechols. The behavior of 2-hydroxy-8,9-dehydroestrone was found to be more complex than 4-hydroxy-8,9-dehydroestrone as GSH conjugates resulting from 2-hydroxy-8,9-dehydroestrone were detected even without oxidative enzyme catalysis. Under physiological conditions, 2-hydroxy-8,9-dehydroestrone isomerized to 8-hydroxyequilenin to form the very stable 2-hydroxyequilenin catechol; however, 4-hydroxy-8,9-dehydroestrone was found to be stable under similar conditions. Finally, preliminary studies conducted with the human breast tumor S-30 cell lines demonstrated that the catechol metabolites of 8,9-dehydroestrone were much less toxic than 4-hydroxyequilenin (20-40-fold). These results suggest that the catechol metabolites of 8,9-dehydroestrone may have the ability to cause cytotoxicity in vivo primarily through formation of o-quinones; however, most of the adverse effects of Premarin estrogens are likely due to formation of 4-hydroxyequilenin o-quinone from equilin and equilenin.

  DOI：

  10.1021/tx010049y

文献信息

• 17-difluoromethylene-estratrienes
  申请人：Schering Aktiengesellschaft

  公开号：US06018062A1

  公开（公告）日：2000-01-25

  This invention describes the new 17-difluoromethylene-estratrienes of general formula I ##STR1## in which R.sup.1 means a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group, R.sup.5 means a methyl or ethyl group, and R.sup.2 means a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group in .alpha.- or .beta.-position, R.sup.3 means a hydrogen atom or a C.sub.1 -C.sub.10 alkyloxy group in .alpha.- or .beta.-position, R.sup.4 means a hydrogen atom in .alpha.- or .beta.-position, and A, B, D, E and G each mean a hydrogen atom, and optionally at least one of substituent pairs G and R.sup.2, R.sup.2 and R.sup.4, R.sup.4 and A, A and R.sup.3, B and D, D and E mean a double bond.

  这项发明描述了一般式I的新型17-二氟甲基醇基雌三烯类化合物，其中R.sup.1表示氢原子或C.sub.1-C.sub.10烷基基团，R.sup.5表示甲基或乙基基团，R.sup.2表示α-或β-位的氢原子或C.sub.1-C.sub.10烷基基团，R.sup.3表示α-或β-位的氢原子或C.sub.1-C.sub.10烷氧基团，R.sup.4表示α-或β-位的氢原子，A、B、D、E和G各自表示氢原子，并且可选地至少有一个取代基对G和R.sup.2、R.sup.2和R.sup.4、R.sup.4和A、A和R.sup.3、B和D、D和E表示双键。
• Totally synthetic steroid hormones—XX
  作者：R.P. Stein、G.C. Buzby、H. Smith

  DOI：10.1016/s0040-4020(01)92768-1

  日期：1970.1

  9α-epoxy-estra-1,3,5(10)-trienes IIIa–c and estra-1,3,5(10),9(11)-tetraen-8α-ols IVa–c with mineral acid to mixtures of estra-1,3,5(10),6,8-pentaenes of type XIX and estra-1,3,5 (10), 8,14-pentaenes of type XX. Fused MeMgI constitutes an excellent reagent for demethylating acid-labile steroids such as the estra-1,3,5(10),8-tetraenes II, the estra-1,3,5(10)-trien-8α-ols V and the estra-1,3,5(10), 7-tetraenes

  从一般II类的Est​​ra-1,3,5（10），8-四烯开始，开发了一系列新的雌马酚（Ia）和同源化合物的新合成方法。†这些合成中的关键反应是a的氧化四烯II与米氯过苯甲酸，以p的酸将得到的环氧化物III的重排嘉1·42–4·21形成estra-1,3,5（10），9（11）-丁烯-8α-olIV，将9（11）-烯烃键催化加氢得到estra-1， 3,5（10）-trien-8α-olV，然后用甲磺酰氯或三氯氧磷在二甲基甲酰胺中脱水，形成estra-1,3,5（10），7-四烯。迄今为止，开发的最有效的马匹蛋白合成方法是从3-甲氧基-1,3,5（10），8-丁烯-17β-olIIc转变为3-甲氧基-1,3,5（10），7-丁烯- 17β-olXIIIb（通过上述方法），最后通过二甲基化和氧化以生成等分体Ia，总产率为37·7％。8β，9α-环氧-estra-1,3,5（10）-三烯IIIa–c和estra-1
• Synthesis of Ring B Unsaturated Estriols. Confirming the Structure of a Diagnostic Analyte for Smith−Lemli−Opitz Syndrome
  作者：Li-Wei Guo、Cedric H. L. Shackleton、William K. Wilson

  DOI：10.1021/ol016224j

  日期：2001.8.9

  [structure: see text] Brief partial syntheses are described for ring B unsaturated estriols, which are candidate metabolites diagnostic for Smith-Lemli-Opitz syndrome prenatally. These steroids are also likely metabolites of the Premarin preparation used in estrogen replacement therapy. Equilin (8) was converted in three steps to 7-dehydroestriol, which was isomerized to 8-dehydroestriol. The simplicity

  [结构：见正文]描述了B环不饱和雌激素的简要部分合成，这些B环是产前诊断Smith-Lemli-Opitz综合征的候选代谢物。这些类固醇也可能是用于雌激素替代疗法的Premarin制剂的代谢产物。分三步将Equilin（8）转化为7-脱氢雌三醇，将其异构化为8-脱氢雌三醇。转化的简单性掩盖了这些以前无法获得的代谢物及其合成前体的不稳定性。
• Synthesis of 13-alkyl-gon-4-ones
  申请人：Smith; Herchel

  公开号：US03959322A1

  公开（公告）日：1976-05-25

  The preparation of 13-methylgon-4-enes and novel 13-polycarbonalkylgon-4-enes by a new total synthesis is described. 13-Alkylgon-4-enes having progestational, anabolic and androgenic activities are prepared by forming a tetracylic gonane structure unsaturated in the 1,3,5(10),9(11) and 14-positions, selectively reducing in the B- and C-rings, and converting the aromatic A-ring compounds so-produced to gon-4-enes by Birch reduction and hydrolysis.

  本文描述了一种新的全合成方法，制备了13-甲基gon-4-烯和新型的13-聚碳烷基gon-4-烯。通过形成一个在1,3,5(10),9(11)和14-位不饱和的四环戊烷骨架，选择性地在B环和C环中还原，然后通过Birch还原和水解将产生的芳香A环化合物转化为gon-4-烯，制备了具有孕激素、增强剂和雄激素活性的13-烷基gon-4-烯。
• Synthesis of gon-4-enes
  申请人：Smith; Herchel

  公开号：US04002746A1

  公开（公告）日：1977-01-11

  1. A therapeutic composition having progestational activity comprising as active ingredient a 17-aliphatic carboxylic acid ester of 17.alpha.-ethynyl-18-methyl-19-nortestosterone and a pharmaceutical carrier for said compound.

  一种具有孕激素活性的治疗组合物，其包括作为活性成分的17-脂肪族羧酸酯化合物，该化合物为17α-乙炔基-18-甲基-19-去氢睾酮的酯化合物，并包含药用载体。